Derivatives of sulindac, use thereof and preparation thereof

Details Derivatives of sulindac, use thereof and preparation thereof Derivatives of sulindac, use thereof and preparation thereof

2007-01-04

2011-10-25

Chu, Yong (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S618000, C514S428000, C514S252120, C514S319000, C514S277000, C544S399000, C544S161000, C546S205000, C546S340000, C548S571000, C564S162000

Reexamination Certificate

active

08044048

ABSTRACT:
Derivatives of sulindac are provided along with pharmaceutical compositions containing them and use for precancerous conditions and treating cancer. Derivatives of sulindac are also suitable for treating chronic inflammatory conditions. A method for preparing the derivatives is also provided.

REFERENCES:
patent: 3161654 (1964-12-01), Shen et al.
patent: 3647858 (1972-03-01), Hinkley et al.
patent: 3654349 (1972-04-01), Shen et al.
patent: 3851063 (1974-11-01), Shen et al.
patent: 4423075 (1983-12-01), Dvornik et al.
patent: 5401774 (1995-03-01), Pamukcu et al.
patent: 5475021 (1995-12-01), Marnett et al.
patent: 5643959 (1997-07-01), Pamukcu et al.
patent: 5858694 (1999-01-01), Piazza et al.
patent: 5942520 (1999-08-01), Pamukcu et al.
patent: 5973191 (1999-10-01), Marnett et al.
patent: 6063818 (2000-05-01), Sperl et al.
patent: 6071934 (2000-06-01), Sperl et al.
patent: 6130053 (2000-10-01), Thompson et al.
patent: 6166053 (2000-12-01), Sperl et al.
patent: 6200771 (2001-03-01), Liu et al.
patent: 6403831 (2002-06-01), Sperl et al.
patent: 2001/0034361 (2001-10-01), Kalgutkar et al.
patent: 2004/0192929 (2004-09-01), Allegrini et al.
patent: 2005/0090553 (2005-04-01), Shapiro
patent: 2005/0250839 (2005-11-01), Marnett et al.
patent: 958032 (1974-11-01), None
patent: 0881300 (2001-01-01), None
patent: WO-9821195 (1998-05-01), None
patent: WO 0011022 (2000-03-01), None
patent: WO 0027194 (2000-05-01), None
Kalgutkar et al., Biochemically Based Design of Cyclooxygenase-2 (COX-2) Inhibitors: Facile Conversion of Nonsteroidal Antiinflammatory Drugs to Potent and Highly Selective COX-2 Inhibitors, PNAS, Jan. 18, 2000, vol. 97, No. 2, 925-930.
Kalgutkar et al., Ester and Amide Derivatives of the Nonsteroidal Antiinflammtory Drug, Indomethacin, As Selective Cyclooxygenase-2 Inhibitors, J. Med. Chem, 2000, vol. 43, No. 15, 2860-2870.
Kalgutkar et al., Amide Derivatives of Meclofenamic Acid as Selective Cyclooxygenase-2 Inhibitors, Bioorg. Med. Chem. Lett. 12 (2002) 521-524.
English language translation of Office Action dated Apr. 2, 2010 from corresponding Eurasian Application No. 200870148/(OFE/0808/0005).
Office Action dated Mar. 16, 2010 from corresponding Canadian Application No. 2,635,093.
Documents filed May 26, 2010 with EPO in corresponding European Application No. 07716225.3-2112.
English language translation of Office Action dated Mar. 23, 2010 from corresponding Chinese Application No. 200780001936.4.
Communication dated Nov. 24, 2009 and Supplementary European Search Report dated Oct. 6, 2009 in corresponding European Application No. 07716225.3-2112.
Examination Report dated Mar. 10, 2010 from corresponding New Zealand Application No. 569370.
Bennett et al., Increased Survival of Cancer-Bearing Mice Treated With Inhibitors of Prostaglandin Synthesis Alone or With Chemotherapy, Br. J. Cancer (1982) 45, 762.
Timothy A. Chan, Nonsteroidal Anti-Inflammatory Drugs, Apoptosis, and Colon-Cancer Chemoprevention, The Lancet Oncology, vol. 3, Mar. 2002, 166-174.
Chau et al., Cyclooxygenase Inhibition In Cancer—A Blind Alley or a New Therapeutic Reality?, N. Engl. J. Med., vol. 346, No. 14, Apr. 4, 2002, 1085-1087.
DuBois et al., Editorials, Journal of the National Cancer Institute, vol. 94, No. 23, Dec. 4, 2002.
Duggan et al., The Disposition of Sulindac, Clinical Pharmacology and Therapeutics, vol. 21, No. 3, Nov. 4, 1976, 326-335, (1979).
Duggan et al., Kinetics of the Tissue Distributiions of Sulindac and Metabolites, Drug and Metabolism and Dispositions, Sulindac Pharmacokinetics, vol. 8, No. 4, pp. 241-246.
Duggan et al., Identification of the Biologically Active Form of Sulindac, The Journal of Pharmacology and Experimental Therapeutics, vol. 201, No. 1, 1977, pp. 8-13.
Duggan et al., Comparative Disposition of Sulindac and Metabolites in Five Species, Biological Pharmacology, vol. 27, pp. 2311-2320, (1978).
Ervin Y. Eaker, Gastrointestinal Injury Related to use of Nonsteroidal Anti-Inflammatory Drugs, Gatrointestinal Diseases Today, vol. 6, No. 6, 1977, pp. 1-8.
Elliott et al., A Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug Accelerates Gastric Ulcer Healing in Rate, Gastroenterology 1995, vol. 109, pp. 524-530.
Amy M. Fulton, Inhibition of Experimental Metastasis With Indomethacin: Role of Macrophages and Natural Killer Cells, Prostaglandins, Mar. 1988 vol. 35 No. 3, pp. 413-425.
Giardiello et al., Treatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous Polyposis, New England Journal of Medicine, vol. 328, 1993, No. 18, pp. 1313-1316.
Hial et al., Alternation of Tumor Growth by Aspirin and Indomethacin: Studies with Two Transplantable Tumors in Mouse, European Journal of Pharmacology, 37 (1976) 367-376.
Janne et al., Chemoprevention of Colorectal Cancer, New England Journal of Medicine, 2000, vol. 342, No. 26, 1960-1968.
Karaguni et al., New Indene-Derivatives with Anti-Proliferative Properties, Bioorganic & Medicinal Chemistry Letters, 12 (2002) 709-713.
Karaguni et al., The New Sulindac Derivative IND 12 Reverses Ras-induced Cell Transformation, Cancer Research 62, 1718-1723, Mar. 15, 2002.
Labayle et al., Sulindac Causes Regression of Rectal Polyps in Familial Adenomatous Polyposis, Gastroenterology, 1991, vol. 101, pp. 635-639.
Llorens e tal., Differential Binding Mode of Diverse Cyclooxygenase Inhibitors, Journal of Molecular Graphics and Modelling, 20 (2002), pp. 359-371.
Lynch et al., Mechanism of Inhibition of Tumour Growth By Aspirin and Indomethacin, Br. J. Cancer, (1978) 38, 503.
Mahmud et al., A Unifying Hypothesis for the Mechanism of NSAID Related Gastrointestinal Toxicity, Annals of the Rheumatic Diseases, 1996, vol. 55, pp. 211-213.
Moorghen et al., A Protective Effect of Sulindac Against Chemically-Induced Primary Colonic Tumors in Mice, Journal of Pathology, vol. 156, 341-347 (1988).
Moorghen et al., The Effect of Sulindac on Colonic Tumor Formation in Dimethylhydrazine-treated Mice, Acta histochemica, Suppl.-Band XXXIX, S. 195-199 (1990).
Mukherjee et al., Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors, JAMA, 2001, vol. 286, pp. 954-959.
Myers et al., Proapoptotic Anti-Inflammatory Drugs, Urology, 57 (Supplemental 4A), Apr. 2001, pp. 73-76.
Nugent et al., Randomized Controlled Trial of the Effect of Sulindac on Duodenal and Rectal Polyposis and Cell Proliferation in Patients with Familial Adenomatous Polyposis, Br. J. Surg., 1993, vol. 80, December, pp. 1618-1619.
Biff Palmer, Renal Complications Associated with Use of Nonsteroidal Anti-Inflammatory Agents, Journal of Investigative Medicine, vol. 43, No. 6, Dec. 1995, pp. 516-533.
Piazza et al., Apoptosis Primarily Accounts for the Growth-Inhibitory Properties of Sulindac Metabolites and Involves a Mechanism That Is Independent of Cyclooxygenase Inhibition, Cell Cycle Arrest, and p53 Induction, Cancer Research, 57, 2452-2459, Jun. 15, 1997.
Piazza et al., Sulindac Sulfone Inhibits Azoxymethane-induced Colon Carcinogenesis in Rats Without Reducing Prostaglandin Levels, Cancer Research, 57, 2909-2915, Jul. 15, 1997.
Piazza et al., Exisulind, A Novel Proapoptotic Drug, Inhibits Rat Urinary Bladder Tumorigenesis, Cancer Research, 61, 3961-3968, May 15, 2001.
Piazza et al., Antineoplastic Drugs Sulindac Sulfide and Sulfone Inhibit Cell Growth by Inducing Apoptosis, Cancer Research, 55, 3110-3116, Jul. 15, 1995.
Pollard et al., Prolonged Antitumor Effect of Indomethacin on Autochthonous Intestinal Tumors in Rats, JNCI, vol. 70, No. 6, Jun. 1983.
Shen et al., Chemical and Biological Studies on Indomethacin, Sulindac and Their Analogs, pp. 89-245, (1977).
Strong et al., Sulindac Metabolism: The Importance of An Intact Colon, Clin. Pharm. Th. vol. 38, No. 4, Oct. 1983, pp. 387-393.
Strul et al., Non-Steroidal Anti-Inflammatory Drugs and Selective Apoptotic Anti-Neoplastic Drugs in the Prevention of Colorectal Cancer: The Role of Super Aspirins, IMAJ, vol. 2, Sep. 2000, pp. 695-702.
Swanson et al., Sulindac Disposition When Given Once and Twice Daily, Clin. Pharmacol. Ther., vol. 12, No. 3, Sep. 1982. pp. 397-403.
Tarazi et al., Sulindac-Ass

Affiliated with

Also associated with

Rating

Derivatives of sulindac, use thereof and preparation thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Derivatives of sulindac, use thereof and preparation thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of sulindac, use thereof and preparation thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4274592